Desktop version

Home arrow Sociology

  • Increase font
  • Decrease font

<<   CONTENTS   >>

Influenza and Common Cold

Table of Contents:

Many early studies investigating the prophylaxis and treatment of influenza and common cold infections explored the link between the consumption of eggs and improved outcomes. We now know that PEA is abundant in egg yolks, and the anti-inflammatory and immune-modulating effects seen in these studies were most likely due to the ingestion of PEA. Several studies in the 1960s and 1970s explored the use of PEA as a prophylaxis and treatment of influenza and the common cold. The results of these trials showed that patients treated with PEA had fewer episodes of fever, headache, sore throat, and incidence of disease compared to placebo.6 Given that there is still no absolute treatment for the common cold and the varied successes of recent influenza vaccines, PEA provides a valid option for treatment and prevention.


Palmitoylethanolamide appears to have many applications in inflammatory and immune-modulatory diseases. The profound effects on PPAR-a, NF-кВ, inflammatory cytokines, COX, and substance P mast cell activation support the use of PEA in the treatment of pain, neurodegenerative diseases, neural injury, ophthalmic disorders, and viral infections, among a multitude of other diseases. With such a phenomenal safety profile as well as no documented drug or disease interactions, it is a wonder that PEA is not utilized more often.


  • 1. Skaper S.D., Facci L., Barbierato M. et al. /V-palmitoylethanolamine and neuroinflammation: a novel therapeutic strategy of resolution. Mol Neurobiol 2015:52(2):1034—1042. doi: 10.1007/sl2035-015-9253-8.
  • 2. Lambert D.M., Vandevoorde S., Jonsson K., Fowler C.J. The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr Med Chem 2002;9(6):663-674.
  • 3. Alhouayek M., Muccioli G.G. Flarnessing the anti-inflammatory potential of palmitoylethanolamide. Drug Discov Today 2014;19(10): 1632-1639. doi:10.1016/j.drudis.2014.06.007.
  • 4. Keppel Hesselink J.M., Kopsky D.J., Witkamp R.F. Palmitoylethanolamide (PEA)-‘promiscuous’ antiinflammatory and analgesic molecule at the interface between nutrition and pharma. PharmaNutrition 2014;2(1): 19-25. doi: 10.1016/j.phanu.2013.11.127.
  • 5. Keppel Hesselink J.M.. HekkerT.A.M. Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. J Pain Res 2012;5:437- 442. doi:10.2147/JPR.S32143.
  • 6. Keppel Hesselink J.M.K., de Boer T, Witkamp R.F. Palmitoylethanolamide: a natural body-own antiinflammatory agent, effective and safe against influenza and common cold. IntJInflam 2013;2013:1-8. doi:10.1155/2013/151028.
  • 7. Mannelli L.D.C., D’Agostino G., Pacini A. et al. Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. Mediators Inflam 2013;2013:1-12. doi: 10.1155/2013/328797.
  • 8. Sasso O., Russo R., Vitiello S. et al. Implication of allopregnanolone in the antinociceptive effect of /V- pa 1 m i t oy 1 et ha no 1 a m i d e in acute or persistent pain. Pain 2012;153(1):33—41. doi: 10.1016/j. pain.2011.08.010.
  • 9. Gatti A.. Lazzari M., Gianfelice V., Di Paolo A., Fabrizio Sabato A., Sabato A.F. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopethogenesis. Pain Med 2012;13(9):1121—1130. doi:10.1111/j. 1526-4637.2012.01432.x.
  • 10. Keppel Hesselink J.M. Effectiveness of the association micronized N-palitoylethamolarnine (PEA)- tranpolydatin in the treatment of chronic pelvic pain. EurJ Obstet Gynecol Reprod Biol 2011 ;159(2):488- 489. doi: 10.1016/j.ejogrb.2011.06.005.
  • 11. Tartaglia E., Armentano M., Giugliano B. et al. Effectiveness of the association /V- pa 1 m i t oy le t h a n ol a in i ne and transpolydatin in the treatment of primary dysmenorrhea. J Ped Adolesc Gynecol 2015;28(6):447— 450. doi: 10.1016/j.jpag.2014.12.011.
  • 12. Cobellis L., Castaldi M.A., Giordano V. et al. Effectiveness of the association micronized A'-Palmitoylethanoleamine (PEA) - transpolydatin in the treatment of chronic pain related to endometriosis after laproscopic assessment: a pilot study. Enr J Obstet Gynecol Reprod Biolo 2011;158(1):82- 86. doi:10.1016/j.ejogrb.2011.04.011.
  • 13. Giugliano E., Cagnazzo E., Soave I., Lo Monte G., Wenger J.M., Marci R. The adjuvant use of N-palmitoylethanolamine and transpolydatin in the treatment of endometriotic pain. Ear J Obstet Gynecol Reprod Biolo 2013;168(2):209-213. doi:10.1016/j.ejogrb.2013.01.009.
  • 14. Del Giorno R., Skaper S., Paladini A.. Varrassi G., Coaccioli S. Palmitoylethanolamide in fibromyalgia: results from prospective and retrospective observational studies. Pain Ther 2015;4(2):169—178. doi: 10.1007/s40122-015-0038-6.
  • 15. Fichna J., Wood J.T.. Papanastasiou M. et al. Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study. PLOS ONE 2013;8(12):l-8. doi:10.1371/journal.pone.0085073.
  • 16. Russo R., Cristiano C., Avagliano C. et al. Gut-brain axis: role of lipids in the regulation of inflammation. pain and CNS diseases. CurrMedChem 2018;25(32):3930-3952. doi: 10.2174/09298673246661702 16113756.
  • 17. Cremon C., Stanghellini V., Barbara M.R. et al. Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. Aliment Pharmacol Tiler 2017;45(7):909-922. doi:10.1111/apt. 13958.
  • 18. Esposito E., Impellizzeri D., Mazzon E., Paterniti I., Cuzzocrea S. Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson’s disease. PLOS ONE 2012;7(8): 1—14. doi:10.1371/ journal.pone.0041880.
  • 19. Brotini S., Schievano C., Guidi L. Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson’s disease. CNS Neurol Disord Drug Targets 2017;16(6):705—713. doi:10.2174/187 1527316666170321124949.
  • 20. Scuderi C., Stecca C., Valenza M. et al. Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer’s disease. Cell Death Dis 2014;5:el419. doi:10.1038/ cddis.2014.376.
  • 21. Parrella E., Porrini V., Iorio R. et al. PEA and luteolin synergistically reduce mast cell-mediated toxicity and elicit neuroprotection in cell-based models of brain ischemia. Brain Res 2016;1648(A):409—417. doi:10.1016/j.brainres.2016.07.014.
  • 22. Guida F., Boccella S., Iannotta M. et al. Palitoylethanolamide reduces neuropsychiatric behaviors by restoring cortical electrophysiological activity in a mouse model of mild traumatic brain injury. Front Pharmacol 2017;8(95):1-14. doi:10.3389/fphar.2017.00095.
  • 23. Impellizzeri D., Cordaro M., Bruschetta G. et al. /V-palmitoylethanolamine-oxazoline as a new therapeutic strategy to control neuroinflammation: neuroprotective effects in experimental models of spinal cord and brain injury. J Neurotrauma 2017;34(18):2609-2623. doi:10.1089/neu.2016.4808.
  • 24. Andresen S.R., Bing J., Hansen R.M. et al. Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trial. Pain 2016; 157(9):2097—2103. doi:10.1097/j.pain.0000000000000623.
  • 25. Keppel Hesselink J.M., Costagliola C., Fakhry J., Kopsky D.J. Palmitoylethanolamide, a natural retino- protectant: its putative relevance for the treatment of glaucoma and diabetic retinopathy. J Ophthalmol 2015:2015:1 -9. doi: 10.1155/2015/430596.
  • 26. Costagliola C„ Romano M.R., dell’Omo R., Russo A., Mastropasqua R., Semeraro F. Effect of palmitoylethanolamide on visual field damage progression in normal tension glaucoma patients: results of an open-label six-month follow-up. J Medl Food 2014;17(9):949-954. doi:10.1089/jmf.2013.0165.
  • 27. Schifilliti C., Cucinotta L., Fedele V., Ingegnosi C.,Luca S., Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat 2014:1-5. doi: 10.1155/2014/849623.
  • 28. Cocito D„ Peci E., Ciaramitaro P., Merola A., Lopiano L. Short-term efficacy of ultramicronized palmi- toylethnaolamide in peripheral neuropathic pain. Pain ResTreat204204:1-4. doi: 10.1155/2014/854560.
<<   CONTENTS   >>

Related topics